Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683421 · ClinicalTrials.gov registry record · Phase 1
Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
A Phase 1 study, sponsored by Navidea Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02683421 is a Phase 1 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT02683421, a Phase 1 study, has completed, sponsored by Navidea Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with active RA and concordance with clinical symptomology.
Interventions
- DRUG Tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683421
The ClinicalTrials.gov registry entry for NCT02683421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tilmanocept is the first listed.
NCT02683421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683421 about?
NCT02683421 is a clinical study titled "Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging". Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with active RA and concordance with clinical symptomology.
What is the current status of trial NCT02683421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02683421?
The interventions under investigation include: Tilmanocept (DRUG).
Who is sponsoring clinical trial NCT02683421?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.